Magdolna Hornyak1, Mandy Sohr, Michael Busse. 1. Interdisciplinary Pain Center, University Medical Center, Breisacher Strasse 64, 79106 Freiburg, Germany. magdolna.hornyak@uniklinik-freiburg.de
Abstract
BACKGROUND: Although "uncomfortable and unpleasant" limb sensations are a core symptom of restless legs syndrome (RLS), change in sensory symptomatology is usually not evaluated as a treatment outcome. METHODS: In two double-blind trials, patients with idiopathic RLS (n=357 in trial 615 and 398 in trial 604) were randomized to placebo or pramipexole (optimized at 0.125, 0.25, 0.50, or 0.75 mg/day). For entry, trial 604 also required at least moderate mood disturbance. In both trials, 12-week change in RLS-related limb pain was assessed using a 100-mm visual analogue scale (VAS). RESULTS: At baseline, approximately 75% of patients had limb-pain scores >30. Treatment with pramipexole yielded significant score reduction as early as day 5. At week 12, median score reduction for pramipexole relative to placebo was -33.5 vs. -11.0 (p<0.0001) in trial 615 and -31.0 vs. -11.0 (p<0.0001) in trial 604. CONCLUSIONS: Painful sensations may be more frequent in RLS than has previously been appreciated, and their amelioration may be a facet of pramipexole's benefit even in patients with concurrent mood disturbance. Limb pain assessment, e.g., by a VAS, is a useful measure of change in RLS symptom severity.
RCT Entities:
BACKGROUND: Although "uncomfortable and unpleasant" limb sensations are a core symptom of restless legs syndrome (RLS), change in sensory symptomatology is usually not evaluated as a treatment outcome. METHODS: In two double-blind trials, patients with idiopathic RLS (n=357 in trial 615 and 398 in trial 604) were randomized to placebo or pramipexole (optimized at 0.125, 0.25, 0.50, or 0.75 mg/day). For entry, trial 604 also required at least moderate mood disturbance. In both trials, 12-week change in RLS-related limb pain was assessed using a 100-mm visual analogue scale (VAS). RESULTS: At baseline, approximately 75% of patients had limb-pain scores >30. Treatment with pramipexole yielded significant score reduction as early as day 5. At week 12, median score reduction for pramipexole relative to placebo was -33.5 vs. -11.0 (p<0.0001) in trial 615 and -31.0 vs. -11.0 (p<0.0001) in trial 604. CONCLUSIONS:Painful sensations may be more frequent in RLS than has previously been appreciated, and their amelioration may be a facet of pramipexole's benefit even in patients with concurrent mood disturbance. Limb pain assessment, e.g., by a VAS, is a useful measure of change in RLS symptom severity.
Authors: R Nisha Aurora; David A Kristo; Sabin R Bista; James A Rowley; Rochelle S Zak; Kenneth R Casey; Carin I Lamm; Sharon L Tracy; Richard S Rosenberg Journal: Sleep Date: 2012-08-01 Impact factor: 5.849
Authors: Anouk D Rozeman; Truus Ottolini; Diana C Grootendorst; Oscar J M Vogels; Roselyne M Rijsman Journal: J Clin Sleep Med Date: 2014-08-15 Impact factor: 4.062
Authors: Mark P DeAndrade; Russell L Johnson; Erica L Unger; Li Zhang; Thomas van Groen; Karen L Gamble; Yuqing Li Journal: Hum Mol Genet Date: 2012-06-07 Impact factor: 6.150
Authors: Neal Hermanowicz; Aaron Ellenbogen; Gordon Irving; Mark Buchfuhrer; Mark J Jaros; Gwendoline Shang; Richard Kim Journal: CNS Drugs Date: 2016-05 Impact factor: 5.749